Member Info for Cliveas

Transforming from a research and development company into one with commercial products in 2022!

Fully funded! What else does the market want?

Commenting on the performance and outlook, Sara Barrington, Chief Executive Officer, said: "We have been delighted with the progress that Verici Dx has made, both during 2021 and at the start of 2022, either delivering strongly or exceeding against the expectations and strategic milestones set out at IPO. We are well placed to continue this momentum throughout the rest of the year, and by the end of 2022 we will have firmly moved from being a research and development company to one with a commercial product.

"Following our March 2022 fundraise, we have the necessary resources to not only commercialise our well-differentiated core products, but also progress the development of Protega™, and to find new exciting growth opportunities. Our recent announcement regarding the positive headline data from our international validation study for Tuteva™ was a significant milestone, as it demonstrated the significantly higher Positive Predictive Value (PPV) of Tuteva™ versus currently available blood tests. This paves the way for a commercial launch in the United States later in 2022. We look forward to announcing the outcomes from the validation study for Clarava™ in the coming weeks.

"Over the rest of the year, a health economics model is expected to be completed to help support our imminent commercial launches, and we will also work to engage in clinical utility and real-world evidence studies to support adoption of our two lead products."

Fill your boots down here imho.

GL.

b.grn update: Welsh Freeport, b.grn welcomes decision
Anglesey, 12th May 2022. b.grn Group Ltd, a company developing a portfolio of waste-to-fuel plants across the UK, is pleased to note today’s news from the UK and Welsh Governments that agreement has been reached to establish a new Freeport under a joint assessment of bids from interested locations.

Following b.grn’s Richard Parris’ meeting with Virginia Crosbie, Member of Parliament for Ynys Môn, the Company welcomes the announcement that £26.0 million in UK Government funding will be made available to back a Welsh Freeport. b.grn has supported Ms. Crosbie’s campaign for this status and wishes her and her team success in the forthcoming bidding process.

Freeport status is important for the community and economy. b.grn’s own plans, previously announced as Project Panad, for a waste-to-fuel operation on Anglesey will generate considerable economic and social value. The Company believes that this is consistent with the underlying principles of job creation and environmental impact espoused by both Governments in the announcement today.

Consistent with the Freeport news, b.grn today announces that its has retained Lambert Hampton Smith in Cardiff (“LHS”) to advise the Company on its planned purchase of the Anglesey site. LHS will support the Company in its engagement with the Administrators of the Holyhead site, reinforcing b.grn’s economic and social proposals for the site’s redevelopment.

Richard Parris of b.grn, said:

“Anglesey is an ideal site for b.grn’s operations. It has a skilled local workforce, sufficient space for the scale of operation we require, and the support of its hard-working elected representative. b.grn welcomes the Governments’ decision to fund a Welsh Freeport and congratulates Ms. Crosbie and her team on its campaign to secure this progress. Currently, our decision to locate operations in the Holyhead area is conditional on Freeport status being granted to the area. This levels the playing field with our alternative location in Humberside. The company looks forward to working further with Ms. Crosbie and now, LHS to secure access to this important site.”

Virginia Crosbie, Member of Parliament for Ynys Môn, commented:

“This is a big day for Anglesey, and I will do all I can to ensure that a brilliant bid is put forward to grant Freeport status to Holyhead. Companies like b.grn want to invest in our Island but need certainty over that investment and the incentives to do so. A Freeport here will do just that, and I will be working hard across the board with business, with authorities, and with organisations in North Wales to make the bid a success.”

With Virginia Crosbie MP on board little old SNT is punching above its weight!

GL.

News just released! :

Freeport expected to be announced for Wales after deal between UK and Welsh governments :

A freeport is expected to be announced for Wales today, after months of protracted negotiations between the UK and Welsh Governments.

The most likely location for such a low or no tax port is thought to be Holyhead, with the MP Virginia Crosbie a strong advocate of the idea.

The Secretary of State for Wales, Simon Hart, also suggested in March that Cardiff Airport could become a freeport.

A source told the Daily Post newspaper that Westminster had now addressed Welsh Government concerns over funding and employment protection within the freeport.

First Minister Mark Drakeford had also previously voiced his reservations, saying that “anybody sensible” would be “worried about displacement in freeports”.

But he added in March of last year that those issues were “resolvable” but that the “ball at the moment is in the court of the UK government”.

It was reported before the new year that the idea of setting up freeports in Wales and Scotland may have been “killed” by Treasury civil servants.

But in the House of Commons in January Boris Johnson answered Ynys Môn MP Virginia Crosbie to say that they were still planning on bringing a freeport to Wales, with Michael Gove leading the discussions.

“Can the Prime Minister confirm to me and my Ynys Môn constituents that the UK Government are committed to at least one freeport in Wales?” Virginia Crosbie asked. “Will he update the House on how discussions are progressing with the Welsh Government?”

Boris Johnson replied that “my right honourable Friend the Secretary of State for Levelling Up, Housing and Communities [Michael Gove] is indeed talking to his counterparts in the Welsh Government about establishing a freeport in Wales.

“I urge our friends in the Welsh Government to agree to those plans as a matter of urgency.”

The question came after the Telegraph reported last year that the idea of setting up freeports in Wales and Scotland may have been “killed” by Treasury civil servants.

Prime Minister Boris Johnson and Chancellor Rishi Sunak had previously lauded the free ports as a way of “levelling up” the economy outside of London.

But according to the Telegraph, the Treasury privately feared that freeports would simply result in less tax revenue and “displace” existing investment from elsewhere.

“The Treasury has killed freeports,” a source told the newspaper.

Positive results for Tuteva™ from the international clinical validation study

Performance in blinded multi-centre trial establishes new industry standard in detection of acute kidney transplant rejection and paves way for commercial launch in United States in 2022

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces the successful outcomes from its blinded, international, multi-centre validation study for Tuteva™.

Tuteva™ is the Company's post-transplant blood test focused on acute rejection, including sub-clinical rejection . The results of the validation study show that the test, a next-generation RNA sequencing assay, is demonstrating strong performance in the detection of acute rejection, following a kidney transplant.

The finalised data, to be presented at the American Transplant Congress in June 2022, demonstrates a significantly higher Positive Predictive Value ("PPV") for Tuteva™ than currently available kidney transplant blood tests, without enhancement from clinical features, in a broad validation population. This successfully addresses the unmet need for actionable, novel (immune-pathway) biomarker data in this field which should assist clinicians in improving patient outcomes. These clinically important results position Tuteva™ for a 2022 commercial launch to support the estimated c. 100,000 global patients who undergo kidney transplant procedures annually.

The strong results are particularly noteworthy given that the validation study utilised a generalised 'all-comers' patient population rather than a specific subgroup. The Tuteva™ study was purposefully designed this way to capture the clinical reality of all types of rejection, including sub-clinical, borderline, T Cell-mediated, and antibody-mediated rejection across 14 international transplant centres. The results reflect the wide clinical applicability of the test for comprehensive commercial adoption in a real-world setting.

Dr. Roslyn Mannon, Professor of Internal Medicine, the Vice Chair of Research Mentoring and Academic Development in Internal Medicine, and Associate Chief of Research, Division of Nephrology at University of Nebraska, said: "Clinicians value study results that are reflective of what they see in their patient base in their clinics . Positive validation of Tuteva ™ using a study design for that purpose gives clinicians confidence that this test can support critical clinician decision-making in the complex management of kidney transplant patients. With this positive predictive performance, Tuteva ™ can now warn doctors in advance if kidney rejection is starting or likely to occur, allowing timely intervention to improve graft function and long-term survival."

GL.

Latest Share Chat

Posts (Last 30 Days)

Posts (All Time)

Last Post

Member Since

Share Chat Post Distribution over the last 30 days